McNee et al. reported a process by which the augmented expression of peptidyl arginine deiminase 2 (PADI2) by bone marrow mesenchymal stem cells (BMMSCs) in subjects with MGUS and MM is clearly modified to a malignant plasma cell phenotype. The gene discussed is PADI2; the disease is Miyoshi myopathy.